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Transcatheter Aortic Valve Implantation Using CoreValve by 
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Introduction: Transcatheter aortic valve implantation (TAVI) is now considered as an alternative treatment option for severe 
aortic stenosis (AS) patients who cannot undergo surgical aortic valve replacement (AVR). 
Case report: We describe the first Korean case of transaortic TAVI with mini-sternotomy using CoreValve. A 83-year-old 
woman with severe AS and recent history of non-ST elevation myocardial infarction was referred to our institution for 
TAVI intervention. There was no amenable peripheral vascular access for transfemoral or trans-subclavian approach. Considering 
the relatively high procedural risk of transapical approach in this patient, we performed transaortic TAVI with mini-sternotomy. 
Conclusion: The present case suggests transaortic approach may be an effective and safe strategy for TAVI in high risk 
severe AS patients without eligible femoral or subclavian access routes.
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INTRODUCTION
Surgical aortic valve replacement (AVR) is the treatment 
of choice of symptomatic severe  aortic stenosis (AS). With 
technological advancements, an alternative to surgical 
AVR, transcatheter aortic valve implantation (TAVI) has 
recently emerged and has been performed widely after 
the first case a decade ago.1,2 The most common route 
used to deliver transcatheter aortic valve is femoral artery. 
For patients with significant peripheral arterial diseases, 
especially common femoral or iliac artery stenosis, other 
access approach such as transapical or trans-subclavian 
approach can be considered. For whom with unsuitable 
conditions for previously mentioned routes, direct trans-
aortic access with a mini-sternotomy could be an 
alternative option. In this case report, we describe the 
first Korean case of trans-aortic TAVI using CoreValve 
(Medtronic)  for an 83-year-old woman. 
CASE REPORT
An 83-year-old woman (height, 1.43 m; weight, 40 
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Fig. 1. Transthoracic echocardiography before the transcatheter aortic valve implantation. (A) Parasternal long axis view 
shows heavily calcified stenotic aortic valve, (B) Pressure gradient over aortic valve by Doppler (maximal pressure gradient
97 mmHg, mean pressure gradient 63 mmHg). AV; aortic valve, Ao; aorta, LV; left ventricle, LA; left atrium.
Fig. 2. CT images of aorta and iliofemoral arteries. Bilaterally, iliofemoral arteries were not eligible for the transcatheter
aortic valve implantation route due to insufficient size (diameter <6 mm). CIA; common iliac artery, EIA; external iliac
artery, CFA; common femoral artery.
kg; body mass index, 19.6 kg/m2) with severe AS was 
referred to our institution with recent history of 
non-ST-elevation myocardial infarction. Transthoracic 
echocardiography indicated a heavily calcified aortic valve 
with normal global left ventricular ejection fraction of 63% 
(Fig. 1A). An aortic valve area was 0.6 cm2 by continuity 
equation. The peak and mean aortic pressure gradient 
was 97 mmHg and 63 mmHg, respectively (Fig. 1B). On 
computed tomography (CT), the mean diameter of the 
aortic annulus 19 mm and the perimeter was 60 mm. 
The diameter of ascending aorta was 30 mm. Coronary 
angiography showed one-vessel coronary artery disease 
with a focal stenosis (50% diameter stenosis) at the 
proximal right coronary artery. The patient was considered 
high risk for conventional open heart surgical AVR based 
on the logistic European System for Cardiac Operative 
Risk Evaluation (EuroSCORE) which was calculated to be 
25.93%. On CT angiography, the maximal lumen diameter 
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Fig. 3. Transcatheter aortic valve implantation by transaortic approach. (A) Exposure of ascending aorta by mini-sternotomy,
(B) Insertion of a 18F sheath into ascending aorta, (C) Partial deployment of self-expanding CoreValve within aortic valve,
(D) Complete implantation of CoreValve.
was 5 mm for both common femoral arteries and 6 mm 
for both iliac arteries (Fig. 2). The diameter of the left 
subclavian artery was 5.5 mm.
A multidisciplinary heart team consisted of inter-
ventional cardiologists, cardiac surgeons, cardiac imaging 
specialists and anesthesiologists reviewed the patient and 
decided to perform TAVI. Since a delivery catheter of the 
CoreValve (18 french (F)) requires a vascular route of ≥7 
mm, transfemoral or trans-subclavian route was not 
eligible for TAVI. Transapical approach is not generally 
feasible with CoreValve system. Therefore, we planned 
to perform transaortic TAVI by a mini-sternotomy. The 
procedure was prepared in a hybrid operating room under 
the general anesthesia. A 5F pigtail catheter was 
introduced through the femoral artery and placed in the 
ascending aorta. Aortogram revealed a sufficient length 
(>7 cm) of ascending aorta. Since the CoreValve itself 
is 5 cm long, the distance from the aortic valve to the 
sheath’s tip needs to be at least 6 cm in order to deploy 
the self-expandble CoreValve safely. For rapid ventricular 
pacing during balloon dilation of the aortic valve, a 4F 
balloon flotation temporary pacemaker wire was placed 
in the right ventricle via the femoral vein. After 
mini-sternotomy, ascending aorta was exposed (Fig. 3A) 
and a purse string sutures were made for the insertion 
of a 6F vascular sheath. The stenosed aortic valve was 
crossed with a 0.032 inch guidewire passed supported 
by a 5F Amplatz Left (AL) 1 catheter (Cordis, USA). The 
AL1 catheter was exchanged for pig-tail cathether. An 
Amplatz super stiff (260 cm, Amplatz Cook, Indiana, USA) 
wire was inserted over the pigtail and placed into the 
left ventricle. Thereafter, the 6F vascular sheath was 
exchanged for a 18F sheath (Fig. 3B). After the aortic 
valve was predilated with a 18 mm balloon (Z-med, NuMED 
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Fig. 4. Transthoracic echocardiography after the transcatheter aortic valve implantation. (A) Parasternal long axis view shows
implanted CoreValve, (B) Pressure gradient over aortic valve by Doppler (maximal pressure gradient 17 mmHg, mean pressure
gradient 8 mmHg). AV; aortic valve, Ao; aorta, LV; left ventricle, LA; left atrium.
Fig. 5. Electrocardiogram (ECG) findings. (A) ECG before the procedure, (B) ECG after the procedure.
Inc., Hopkinton, NY, USA) under rapid pacing, a 26 mm 
CoreValve was successfully deployed under fluoroscopic 
guidance (Fig. 3C, D). Aortography immediately after the 
CoreValve deployment demonstrated mild aortic regurgi-
tation (grade II). Transesophageal echocardiography 
showed proper position of the prosthetic valve and 
confirmed mild paravalvular leak. The peak and mean 
transaortic pressure gradient was lowered to 17 mmHg 
and 8 mmHg, respectively (Fig. 4). The patient was 
monitored in a coronary care unit during 3 subsequent 
days for potential complications such as stroke, complete 
atrioventricular block, or vascular events. There was no 
significant interval change in electrocardiogram (ECG) 
findings between before the procedure and after that 
(Fig. 5). She recovered fully without any adverse event 
and was discharged on the 9th day after the procedure. 
The patient is currently being followed for 18 months 
without significant adverse cardiovascular event.
DISCUSSION
TAVI is accepted as an alternative treatment modality 
for patient with severe AS at high surgical risk. Patients 
with an estimated morality risk >20% by logistic 
EuroSCORE or >10% by Society of Thoracic Surgeons (STS) 
score system are generally considered candidates for the 
TAVI procedure. In the literature, TAVI and surgical AVR 
were associated with similar rates of survival at 1 year, 
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although all neurologic events (including major strokes 
and transient ischemic attacks) and vascular complication 
after procedures were more associated with TAVI.2 
Currently two types of stented valves, balloon-expandable 
Edwards SAPIEN valve and self-expandable CoreValve 
systems, are commonly used for TAVI. 
Commonly, TAVI procedure is performed via femoral 
artery because its diameter is generally more than 6 mm 
so that 18F device introducer sheath and delivery catheter 
can be introduced. Small size common femoral or iliac 
arteries are contraindicated for a transfemoral approach. 
There is an increased risk of iliac rupture which can result 
in fatality, when forceful delivery of a large sheath 
attempted in small iliac arteries. In such cases, transaortic 
or trans-subclavian approach is generally recommended. 
Thus, when bilateral iliofemoral arteries are not eligible 
due to concomitant peripheral artery disease, alternative 
routes such as trans-subclavian, transapical, or direct aortic 
access through mini-thoracotomy/sternotomy could be 
considered. In our case, trans-subclavian approach was 
not amenable due to small diameter of subclavian artery. 
Transapical approach is not feasible with CoreValve 
system. Furthermore, transapical approach is known to 
associated with the mortality from LV apical tear or rupture 
at the site of puncture,3 and has also complications 
including LV apical false aneurysm, arrhythmias, and 
echocardiographic hypokinesia or akinesia of the LV 
apex.4-6 With recent experiences, there were no significant 
differences in 30 day mortality or procedural compli-
cations between transapical approach and transaortic 
approach.7 In another study, potential advantages inclu-
ding ease of access and procedure related complication 
(e.g. false aneurysm, wound pain, respiratory dysfunction) 
compared with transapical approach were suggested.8
Direct aortic access can be obtained by mini-sternotomy 
as well as with a right anterior mini-thoracotomy.9 The 
direct aortic approach has advantage of overcoming 
challenging vascular disease, and avoids the risk of 
dislodging atherosclerotic plaque during procedure 
through the aorta that may cause distal embolism and 
subsequent stroke.9 Cannula access is technically easy and 
hemorrhage or late pseudoaneurysm risk is relatively low.8 
Our patient tolerated wound pain very well and showed 
early respiratory and physical recovery without any adverse 
event. To our knowledge, this was the first case of 
successful transaortic TAVI in Korea.
In conclusion, an 83-year-old female patient without 
proper femoral or subclavian artery access successfully 
underwent trans-aortic TAVI via mini-sternotomy. This 
case suggests transaortic approach may be an effective 
and safe strategy for TAVI in high risk severe AS patients 
without eligible femoral or subclavian access routes.
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